Search Results - A. Ooki

  • Showing 1 - 10 results of 10
Refine Results
  1. 1

    Concentration maxima of volatile organic iodine compounds in the bottom layer water and the cold, dense water over the Chukchi Sea in the western Arctic Ocean: a possibility of p... by A. Ooki, S. Kawasaki, K. Kuma, S. Nishino, T. Kikuchi

    Published in Biogeosciences (2016-01-01)
    Get full text
    Article


  2. 2

    Multicenter prospective EN-MARK study: efficacy of third-line trastuzumab deruxtecan and dynamic changes in biomarkers, including HER2 status by A. Ooki, H. Osumi, K. Shimada, N. Machida, H. Hara, M. Takamatsu, N. Ishizuka, Y. Fukuda, W. Hashimoto, K. Yamaguchi

    Published in ESMO Gastrointestinal Oncology (2025-12-01)
    Get full text
    Article


  3. 3

    Real-world clinical impact of first-line immune checkpoint inhibitor-based therapy in advanced esophageal squamous cell carcinoma by M. Tamba, K. Chin, H. Osumi, M. Ogura, S. Fukuoka, S. Udagawa, K. Shimozaki, K. Yoshino, T. Wakatsuki, E. Shinozaki, K. Yamaguchi, A. Ooki

    Published in ESMO Gastrointestinal Oncology (2025-06-01)
    Get full text
    Article


  4. 4

    The clinical utility of an mGPS and SII combined score in patients with advanced gastric cancer treated with nivolumab monotherapy by S. Udagawa, A. Ooki, H. Osumi, K. Yoshino, M. Tamba, K. Shimozaki, S. Fukuoka, T. Wakatsuki, M. Ogura, E. Shinozaki, K. Chin, K. Yamaguchi

    Published in ESMO Gastrointestinal Oncology (2025-06-01)
    Get full text
    Article


  5. 5

    Prognostic nutritional index as a prognostic marker in metastatic esophageal squamous-cell carcinoma treated with immune checkpoint inhibitor by K. Yoshino, M. Tamba, H. Osumi, S. Fukuoka, M. Ogura, S. Udagawa, K. Shimozaki, T. Wakatsuki, E. Shinozaki, K. Yamaguchi, K. Chin, A. Ooki

    Published in ESMO Gastrointestinal Oncology (2025-09-01)
    Get full text
    Article


  6. 6

    Clinical efficacy of nivolumab-based therapy for HER2-negative diffuse-type advanced gastric or gastroesophageal junction adenocarcinoma with peritoneal dissemination by Y. Suzuki, K. Shimozaki, S. Udagawa, K. Chin, H. Osumi, S. Fukuoka, K. Yoshino, M. Tamba, T. Wakatsuki, M. Ogura, E. Shinozaki, K. Yamaguchi, A. Ooki

    Published in ESMO Gastrointestinal Oncology (2025-03-01)
    Get full text
    Article


  7. 7

    Managing zolbetuximab-induced nausea and vomiting: a proposal for a pragmatic approach in clinical practice by K. Shimozaki, A. Ooki, Y. Yamahata, T. Aoyama, K. Yoshino, M. Tamba, S. Udagawa, S. Fukuoka, H. Osumi, T. Wakatsuki, E. Shinozaki, M. Ogura, K. Chin, K. Yamaguchi

    Published in ESMO Gastrointestinal Oncology (2025-03-01)
    Get full text
    Article


  8. 8

    Hypoalbuminemia during zolbetuximab plus chemotherapy for claudin 18.2-positive advanced gastric cancer: a need for caution? by K. Shimozaki, A. Ooki, S. Fukuoka, T. Hirasawa, M. Takamatsu, H. Kawachi, T. Wakatsuki, K. Yoshikawa, K. Yoshino, S. Udagawa, H. Osumi, M. Ogura, E. Shinozaki, K. Chin, K. Yamaguchi

    Published in ESMO Gastrointestinal Oncology (2025-12-01)
    Get full text
    Article


  9. 9

    Real-world outcomes of trifluridine/tipiracil for heavily pretreated patients with advanced gastric cancer by K. Fukuda, I. Nakayama, A. Ooki, D. Kamiimabeppu, K. Shimozaki, H. Osumi, S. Fukuoka, K. Yoshino, M. Ogura, T. Wakatsuki, K. Chin, E. Shinozaki, K. Yamaguchi, D. Takahari

    Published in ESMO Gastrointestinal Oncology (2024-03-01)
    Get full text
    Article


  10. 10

    Safety and efficacy of first-line nivolumab plus chemotherapy for HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: real-world data analysis by K. Shimozaki, K. Fukuda, A. Ooki, I. Nakayama, K. Yoshino, M. Tamba, S. Udagawa, S. Fukuoka, H. Osumi, T. Wakatsuki, D. Takahari, E. Shinozaki, M. Ogura, K. Chin, K. Yamaguchi

    Published in ESMO Gastrointestinal Oncology (2024-09-01)
    Get full text
    Article


Search Tools: